Compuls-BED-Severity

Laval University200 enrolled

Overview

* Binge Eating Disorder (BED) has been fairly recently introduced into the Diagnostic and Statistical Manual 5 psychiatric classification and its severity criteria are still not well established. * Moreover, it remains unclear whether BED is associated with greater metabolic severity or more somatic comorbidities, especially in obesity. * Improved BED severity staging could lead to a better definition of management strategies and , therefore, facilitate screening and care. The investigators' hypothesis is that an improved assessment of the impulsivity-compulsivity spectrum, emotional regulation, attentional impairment and somatic or psychiatric comorbidities will result in a better distinction between the severe form of BED (e.g., highly impulsive and somatically complicated) from milder form (e.g., more compulsive and less somatically complicated).

Study Type

OBSERVATIONAL

Enrollment

200

Conditions

Binge-Eating Disorder

Interventions

ObservationalOTHER

(no intervention)

Eligibility

Medical Language ↔ Plain English

Inclusion Criteria: * men or women aged 1 * participants eligible for bariatric surgery (BMI\>40, or BMI\>35 with severe comorbidities) * participants scheduled for medical evaluation and treatment of obesity at the IUCPQ Obesity Clinic (BMI≥30) * participants scheduled for evaluation and treatment of BED at the CEPIA with obesity (BMI≥30) * for the group with BED: positive BEDS-7 screen and Binge Eating Scale score \>16; * for the control group: have a negative BEDS-7 screen and Binge Eating Scale score\<12 * be fluent in French and able to consent. Exclusion criteria : * participants with severe neurological disorder and/or major neurocognitive deficits; * participants with previous bariatric surgery or with introduction or change of anti-obesity medication (liraglutide or naltrexone/bupropion) in the previous 3 months; * participants who cannot read and/or understand French; * participants under guardianship or curatorship; * participants already included in a study with a conflict of interest with this study; * inability to use a computer or iPad; * inability to access an Internet connection or to visit one of the inclusion sites. Secondary exclusion criteria: * participants with a discordance between BEDS-7 (positive) and Binge Eating Scale (score ≤ 16) results found secondarily * participants who did not participate in part of the assessments (e.g., self-questionnaires or neurocognitive tests) and participants with a rate of missing data\>10%.

Outcomes

Primary Outcomes

Physical and psychological comorbidities

Number of current associated comorbidities to patient with and without BED

Time frame: Inclusion

Binge Eating Scale score

To assess binge eating severity based on the 16-item scale developed by Gormally et al in 1982

Time frame: Inclusion

Secondary Outcomes

Body Mass Index in kg.m-2

\[Anthropometric markers\] weight and height will be combined to report BMI in kg/m\^2

Time frame: Inclusion

Percentage of fat mass in %

\[Anthropometric markers\] Based on impedance data, percentage fat mass will be reported when available

Time frame: Inclusion

Waist and hip circumferences in cm

\[Anthropometric markers\] Waist, hip circumference and Waist-hip ratio will be reported in cm when available

Time frame: Inclusion

Triglycerides in mmol/L

Routine clinical biological markers; part of lipidic profile (when available)

Time frame: Inclusion

Cholesterol HDL and LDL in mmol/L

Routine clinical biological markers; part of lipidic profile (when available)

Time frame: Inclusion

Fasting blood glucose in mmol/L

Routine clinical biological markers, when available.

Time frame: Inclusion

Glycated hemoglobin (HbA1C) in %

Routine clinical biological markers, when available.

Time frame: Inclusion

Insulin in pmol/L

Routine clinical biological markers, when available.

Time frame: Inclusion

Visceral Adiposity Index

The Visceral Adiposity Index (VAI) is a sex-specific mathematical index, based on Waist Circumference (WC), Body Mass Index (BMI), triglycerides (TG) and HDL cholesterol (HDL) levels, indirectly expressing visceral adipose function and insulin sensitivity.

Time frame: Inclusion

UPPS-P Impulsive Behavior Scale short version, S-UPPS-P

To assess the Impulsivity-compulsivity spectrum

Time frame: Inclusion

Obsessive-Compulsive Inventory-Revised, OCI-R

To assess the Impulsivity-compulsivity spectrum

Time frame: Inclusion

Stop Signal Task

To assess the Impulsivity-compulsivity spectrum

Time frame: Inclusion

Difficulties in emotion regulation scale short form, DERS

To assess the emotion regulation spectrum

Time frame: Inclusion

Emotional Go / No-Go Task

To assess the emotion regulation spectrum

Time frame: Inclusion

Adult Attention Deficit Hyperactivity Disorder Self-Report Scale, ASRS

To assess attentional functions

Time frame: Inclusion

Integrated Visual and Auditory Continuous Performance Test, IVA-CPT

To assess attentional functions

Time frame: Inclusion

General Anxiety Disorder (GAD)-7

To assess anxiety disorders risk

Time frame: Inclusion

Patient Health Questionnaire (PHQ)-9

To assess depression disorder risk

Time frame: Inclusion

Compuls-BED-Severity

Overview

Conditions

Interventions

Eligibility

Locations (2)

Outcomes

Primary Outcomes

Secondary Outcomes

Central Contacts